Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy
<b>Objective</b> Patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> (DCIS) by core needle biopsy (CNB) exhibit a significant risk for upstaging on final pathology, which leads to major concerns of whether axillary staging is required at the primary operat...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2019-06-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1425 |
id |
doaj-43a47efdefd74edb8bdd02aea820a204 |
---|---|
record_format |
Article |
spelling |
doaj-43a47efdefd74edb8bdd02aea820a2042020-11-25T01:42:51ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412019-06-0116231231810.20892/j.issn.2095-3941.2018.01592018000159Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsyJing Si0Benlong Yang1Rong Guo2Naisi Huang3Chenlian Quan4Linxiaoxi Ma5Bingqiu Xiu6Yun Cao7Yue Tang8Linxiao Shen9Jiajian Chen10Jiong Wu11Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Oncology, Fudan University, Shanghai Medical College, Shanghai 200032, ChinaDepartment of Oncology, Fudan University, Shanghai Medical College, Shanghai 200032, ChinaDepartment of Oncology, Fudan University, Shanghai Medical College, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China<b>Objective</b> Patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> (DCIS) by core needle biopsy (CNB) exhibit a significant risk for upstaging on final pathology, which leads to major concerns of whether axillary staging is required at the primary operation. The present study aimed to identify clinicopathological factors associated with upstaging in patients preoperatively diagnosed with DCIS by CNB.<b>Methods</b> The present study enrolled 604 patients (cN0M0) with a preoperative diagnosis of pure DCIS by CNB, who underwent axillary staging between August 2006 and December 2015, at Fudan University Shanghai Cancer Center (Shanghai, China). Predictive factors of upstaging were analyzed retrospectively.<b>Results</b> Of the 604 patients, 20.03% (<i>n</i> = 121) and 31.95% (<i>n</i> = 193) were upstaged to DCIS with microinvasion (DCISM) and invasive breast cancer (IBC) on final pathology, respectively. Larger tumor size on ultrasonography (> 2 cm) was independently associated with upstaging [odds ratio (OR) 1.558, <i>P</i> = 0.014]. Additionally, patients in lower breast imaging reporting and data system (BI-RADS) categories were less likely to be upstaged (4B <i>vs</i>. 5: OR 0.435, <i>P</i> = 0.002; 4C <i>vs</i>. 5: OR 0.502, <i>P</i> = 0.001). Overall, axillary metastasis occurred in 6.79% (<i>n</i> = 41) of patients. Among patients with axillary metastasis, 1.38% (4/290), 3.31% (4/121) and 17.10% (33/193) were in the DCIS, DCISM, and IBC groups, respectively.<b>Conclusions</b> For patients initially diagnosed with DCIS by CNB, larger tumor size on ultrasonography (> 2 cm) and higher BI-RADS category were independent predictive factors of upstaging on final pathology. Thus, axillary staging in patients with smaller tumor sizes and lower BI-RADS category may be omitted, with little downstream risk for upstaging.http://www.cancerbiomed.org/index.php/cocr/article/view/1425Ductal carcinoma <i>in situ</i>core needle biopsyaxillary staging |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jing Si Benlong Yang Rong Guo Naisi Huang Chenlian Quan Linxiaoxi Ma Bingqiu Xiu Yun Cao Yue Tang Linxiao Shen Jiajian Chen Jiong Wu |
spellingShingle |
Jing Si Benlong Yang Rong Guo Naisi Huang Chenlian Quan Linxiaoxi Ma Bingqiu Xiu Yun Cao Yue Tang Linxiao Shen Jiajian Chen Jiong Wu Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy Cancer Biology & Medicine Ductal carcinoma <i>in situ</i> core needle biopsy axillary staging |
author_facet |
Jing Si Benlong Yang Rong Guo Naisi Huang Chenlian Quan Linxiaoxi Ma Bingqiu Xiu Yun Cao Yue Tang Linxiao Shen Jiajian Chen Jiong Wu |
author_sort |
Jing Si |
title |
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
title_short |
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
title_full |
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
title_fullStr |
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
title_full_unstemmed |
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
title_sort |
factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> by core needle biopsy |
publisher |
China Anti-Cancer Association |
series |
Cancer Biology & Medicine |
issn |
2095-3941 2095-3941 |
publishDate |
2019-06-01 |
description |
<b>Objective</b> Patients preoperatively diagnosed with ductal carcinoma <i>in situ</i> (DCIS) by core needle biopsy (CNB) exhibit a significant risk for upstaging on final pathology, which leads to major concerns of whether axillary staging is required at the primary operation. The present study aimed to identify clinicopathological factors associated with upstaging in patients preoperatively diagnosed with DCIS by CNB.<b>Methods</b> The present study enrolled 604 patients (cN0M0) with a preoperative diagnosis of pure DCIS by CNB, who underwent axillary staging between August 2006 and December 2015, at Fudan University Shanghai Cancer Center (Shanghai, China). Predictive factors of upstaging were analyzed retrospectively.<b>Results</b> Of the 604 patients, 20.03% (<i>n</i> = 121) and 31.95% (<i>n</i> = 193) were upstaged to DCIS with microinvasion (DCISM) and invasive breast cancer (IBC) on final pathology, respectively. Larger tumor size on ultrasonography (> 2 cm) was independently associated with upstaging [odds ratio (OR) 1.558, <i>P</i> = 0.014]. Additionally, patients in lower breast imaging reporting and data system (BI-RADS) categories were less likely to be upstaged (4B <i>vs</i>. 5: OR 0.435, <i>P</i> = 0.002; 4C <i>vs</i>. 5: OR 0.502, <i>P</i> = 0.001). Overall, axillary metastasis occurred in 6.79% (<i>n</i> = 41) of patients. Among patients with axillary metastasis, 1.38% (4/290), 3.31% (4/121) and 17.10% (33/193) were in the DCIS, DCISM, and IBC groups, respectively.<b>Conclusions</b> For patients initially diagnosed with DCIS by CNB, larger tumor size on ultrasonography (> 2 cm) and higher BI-RADS category were independent predictive factors of upstaging on final pathology. Thus, axillary staging in patients with smaller tumor sizes and lower BI-RADS category may be omitted, with little downstream risk for upstaging. |
topic |
Ductal carcinoma <i>in situ</i> core needle biopsy axillary staging |
url |
http://www.cancerbiomed.org/index.php/cocr/article/view/1425 |
work_keys_str_mv |
AT jingsi factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT benlongyang factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT rongguo factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT naisihuang factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT chenlianquan factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT linxiaoxima factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT bingqiuxiu factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT yuncao factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT yuetang factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT linxiaoshen factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT jiajianchen factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy AT jiongwu factorsassociatedwithupstaginginpatientspreoperativelydiagnosedwithductalcarcinomaiinsituibycoreneedlebiopsy |
_version_ |
1725034705494999040 |